Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

IAP inhibitor APG-1387

A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, IAP inhibitor APG-1387 selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, APG-1387 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IAP antagonist APG-1387
SMAC mimetic APG-1387
Code name:APG 1387
APG1387
SM-1387
Chemical structure:pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, 3,3'-(1,3-phenylenebis(sulfonyl))bis(N-(diphenylmethyl)decahydro-5-(((2S)-2-(methylamino)-1-oxopropyl)amino)-6-oxo-, (5S,5'S,8S,8'S,10aR,10'ar)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search